324 related articles for article (PubMed ID: 27974693)
1. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results.
He X; Xu J; Guo W; Jiang X; Wang X; Zong D
Future Oncol; 2013 Oct; 9(10):1459-67. PubMed ID: 24106897
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of concurrent chemoradiotherapy combined with nimotuzumab for low-risk T4 stage nasopharyngeal carcinoma: A pilot study.
Zhang S; Huang X; Zhou L; Lin S
Medicine (Baltimore); 2018 Sep; 97(38):e12503. PubMed ID: 30235761
[TBL] [Abstract][Full Text] [Related]
5. An open-label, single-arm phase II clinical study of induction chemotherapy and sequential Nimotuzumab combined with concurrent chemoradiotherapy in N3M0 stage nasopharyngeal carcinoma.
Zhang S; Huang X; Zhou L; Wu G; Lin J; Yang S; Chen J; Lin S
J BUON; 2018; 23(6):1656-1661. PubMed ID: 30610791
[TBL] [Abstract][Full Text] [Related]
6. Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study.
Lu Y; Chen D; Liang J; Gao J; Luo Z; Wang R; Liu W; Huang C; Ning X; Liu M; Huang H
BMC Cancer; 2019 Dec; 19(1):1262. PubMed ID: 31888551
[TBL] [Abstract][Full Text] [Related]
7. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a retrospective analysis.
Liu ZG; Zhao Y; Tang J; Zhou YJ; Yang WJ; Qiu YF; Wang H
Oncotarget; 2016 Apr; 7(17):24429-35. PubMed ID: 27016412
[TBL] [Abstract][Full Text] [Related]
8. Effect of nimotuzumab and PF induction chemotherapy combined with concurrent chemoradiotherapy in treating locally advanced nasopharyngeal carcinoma.
Gao M; Yuan T; Zhang F
J BUON; 2021; 26(1):116-123. PubMed ID: 33721441
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Ma BBY; Kam MKM; Leung SF; Hui EP; King AD; Chan SL; Mo F; Loong H; Yu BKH; Ahuja A; Chan ATC
Ann Oncol; 2012 May; 23(5):1287-1292. PubMed ID: 21948811
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
[TBL] [Abstract][Full Text] [Related]
12. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
13. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ
Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605
[TBL] [Abstract][Full Text] [Related]
14. A retrospective paired study: efficacy and toxicity of nimotuzumab versus cisplatin concurrent with radiotherapy in nasopharyngeal carcinoma.
Li HM; Li P; Qian YJ; Wu X; Xie L; Wang F; Zhang H; Liu L
BMC Cancer; 2016 Dec; 16(1):946. PubMed ID: 27955638
[TBL] [Abstract][Full Text] [Related]
15. Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.
Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
Lancet Oncol; 2012 Feb; 13(2):163-71. PubMed ID: 22154591
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of lobaplatin combined with 5-fluorouracil as first-line induction chemotherapy followed by lobaplatin-radiotherapy in locally advanced nasopharyngeal carcinoma: preliminary results of a prospective phase II trial.
Ke LR; Xia WX; Qiu WZ; Huang XJ; Yang J; Yu YH; Liang H; Liu GY; Ye YF; Xiang YQ; Guo X; Lv X
BMC Cancer; 2017 Feb; 17(1):134. PubMed ID: 28202000
[TBL] [Abstract][Full Text] [Related]
17. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Wang F; Jiang C; Ye Z; Sun Q; Liu T; Xu M; Wu P; Shi K; Long B; Rihito A; Masoto S; Fu Z
Oncotarget; 2017 Sep; 8(43):75544-75556. PubMed ID: 29088889
[TBL] [Abstract][Full Text] [Related]
19. Comparison of radiotherapy combined with nimotuzumab vs. chemoradiotherapy for locally recurrent nasopharyngeal carcinoma.
Zong JF; Liang QD; Lu QJ; Liu YH; Xu HC; Chen BJ; Guo QJ; Xu Y; Hu CR; Pan JJ; Lin SJ
BMC Cancer; 2021 Nov; 21(1):1274. PubMed ID: 34823489
[TBL] [Abstract][Full Text] [Related]
20. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]